No HRQoL differences between randomized treatments were seen in elderly lymphoma patients receiving R-CHOP with or without granulocyte colony-stimulating factor [4] or modified CHOP versus an elderly-specific regimen [3]. This evidence concerns the gene CSF3 and lymphoma.